XTX Topco Ltd Takes $78,000 Position in Upstream Bio, Inc. (NASDAQ:UPB)

XTX Topco Ltd acquired a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 12,731 shares of the company’s stock, valued at approximately $78,000.

Other large investors have also made changes to their positions in the company. Orbimed Advisors LLC acquired a new position in Upstream Bio during the fourth quarter worth $93,603,000. Decheng Capital LLC purchased a new stake in shares of Upstream Bio during the fourth quarter worth $54,010,000. TCG Crossover Management LLC purchased a new stake in shares of Upstream Bio during the fourth quarter worth $44,856,000. Enavate Sciences GP LLC purchased a new stake in shares of Upstream Bio during the fourth quarter worth $40,438,000. Finally, Bain Capital Life Sciences Investors LLC purchased a new stake in shares of Upstream Bio during the fourth quarter worth $37,735,000.

Upstream Bio Stock Up 1.7%

Shares of UPB stock opened at $18.93 on Friday. The company has a 50-day moving average of $12.76 and a two-hundred day moving average of $9.92. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $0.32 million. Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%. As a group, analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Upstream Bio from a “sell” rating to a “hold” rating in a report on Friday, June 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $56.50.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.